文献速递牙体牙髓病

利用连接图谱鉴定和验证牙髓炎新型生物标志物及治疗药物

Identification and validation of novel biomarkers and therapeutics for pulpitis using connectivity mapping.
PubMed 文献 · Int Endod J · 2021-06-17

本研究从GEO数据库获取健康与炎症牙髓的微阵列数据,构建不可逆性牙髓炎基因表达特征,并用ssCMap方法筛选治疗化合物。qPCR验证了CCL21、MT1H和AQP9为新上调基因;氟伐他汀和地喹氯铵在离体牙髓炎模型中能降低部分标志物,其中氟伐他汀效果更广。

要点

  • CCL21、MT1H和AQP9被验证为牙髓炎新型生物标志物。
  • 氟伐他汀在离体模型中降低IL8、IL6、CCL21、AQP9和MMP9。
  • 地喹氯铵仅显著降低AQP9,对其他标志物无显著影响。

核心结论

  • AQP9、MT1H和CCL21被鉴定并验证为牙髓炎新型生物标志物。
  • 氟伐他汀和地喹氯铵在离体牙髓炎模型中可降低部分牙髓炎标志物。

研究设计与样本

  • 从GEO数据库检索人类牙髓炎微阵列数据集,通过差异表达分析构建不可逆性牙髓炎基因特征。
  • 使用ssCMap方法鉴定与基因特征高度相关的化合物,并用qPCR验证新基因。
  • 采用离体牙髓炎模型测试化合物效果,通过qPCR、ELISA和多因子阵列测量炎症因子水平。
  • 均值比较使用t检验或ANOVA,显著性水平设为p ≤ .05。

主要发现

  • 差异表达分析在cutoff点p = .0001和p = .000018下构建牙髓炎基因特征。
  • IL8、IL6和MMP9此前已被认定为牙髓炎生物标志物。
  • 新上调基因CCL21、MT1H和AQP9在临床诊断为不可逆性牙髓炎的牙髓组织中经qPCR验证。
  • ssCMap分析鉴定氟伐他汀(他汀类)和地喹氯铵(季铵盐类)与基因特征相关性最强(p = .0001)。
  • 在离体牙髓炎模型中,氟伐他汀降低IL8、IL6、CCL21、AQP9(p < .001)和MMP9(p < .05),地喹氯铵降低AQP9(p < .001)但对其他标志物无显著影响。

关键数值与推荐

  • 牙髓炎基因特征构建的差异表达cutoff点为p = .0001和p = .000018。
  • ssCMap鉴定氟伐他汀和地喹氯铵与基因特征相关性的p = .0001。
  • 氟伐他汀降低IL8、IL6、CCL21、AQP9的p < .001,降低MMP9的p < .05。
  • 地喹氯铵降低AQP9的p < .001,对其他标志物无显著影响。

临床怎么用

  • CCL21、MT1H和AQP9可作为牙髓炎潜在生物标志物,用于辅助诊断或疗效监测研究。
  • 氟伐他汀和地喹氯铵作为已上市药物,经离体模型验证可降低部分牙髓炎标志物,但需进一步体内试验确认。

局限性

  • 研究仅在离体牙髓炎模型中测试化合物效果,尚未进行体内验证。
  • 原文指出这些已上市药物的体内测试是必要的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To create an irreversible pulpitis gene signature from microarray data of healthy and inflamed dental pulps, followed by a bioinformatics approach using connectivity mapping to identify therapeutic compounds that could potentially treat pulpitis. METHODOLOGY: The Gene Expression Omnibus (GEO) database, an international public repository of genomics data sets, was searched for human microarray datasets assessing pulpitis. An irreversible pulpitis gene expression signature was generated by differential expression analysis. The statistically significant connectivity map (ssCMap) method was used to identify compounds with a highly correlating gene expression pattern. qPCR was used to validate novel pulpitis genes. An ex vivo pulpitis model was used to test the effects of the compounds identified, and the level of inflammatory cytokines was measured with qPCR, ELISA and multiplex array. Means were compared using the t-test or ANOVA with the level of significance set at p ≤ .05. RESULTS: Pulpitis gene signatures were created using differential gene expression analysis at cutoff points p = .0001 and .000018. Top upregulated genes were selected as potential pulpitis biomarkers. Among these, IL8, IL6 and MMP9 were previously identified as pulpitis biomarkers. Novel upregulated genes, chemokine (C-C motif) ligand 21 (CCL21), metallothionein 1H (MT1H) and aquaporin 9 (AQP9) were validated in the pulp tissue of teeth clinically diagnosed with irreversible pulpitis using qPCR. ssCMap analysis identified fluvastatin (Statin) and dequalinium chloride (Quaternary ammonium) as compounds with the strongest correlation to the gene signatures (p = .0001). Fluvastatin reduced IL8, IL6, CCL21, AQP9 (p < .001) and MMP9 (p < .05) in the ex vivo pulpitis model, while dequalinium chloride reduced AQP9 (p < .001) but had no significant effect on the other biomarkers. CONCLUSIONS: AQP9, MT1H and CCL21 were identified and validated as novel biomarkers for pulpitis. Fluvastatin and dequalinium chloride identified by the ssCMap as potential therapeutics for pulpitis reduced selected pulpitis biomarkers in an ex vivo pulpitis model. In vivo testing of these licenced drugs is warranted.

来源:Int Endod J,查看原文。版权归原作者所有。

引用

  1. Al-Natour B, Rankin R, McKenna R, et al. Identification and validation of novel biomarkers and therapeutics for pulpitis using connectivity mapping. Int Endod J. 2021. PMID: 33964033. doi:10.1111/iej.13547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。